Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Akero Therapeutics (AKRO) Misses Q2 EPS by 185c
August 12, 2019 7:14 AM EDTAkero Therapeutics (NASDAQ: AKRO) reported Q2 EPS of ($2.21), $1.85 worse than the analyst estimate of ($0.36).
Second Quarter 2019 Financial Results
Research and development expenses for the three-month and six-month periods ended June 30, 2019 were $6.0 million and $10.0 million, respectively, compared to $8.4 million and $8.6 million for the comparable periods in 2018. Research and development expenses in 2019 are attributable to direct costs related to our AKR-001 program, including third-party contract manufacturing, CRO costs associated with the BALANCED trial and internal personnel costs. Research and development expenses in 2018 were primarily attributable to $8.0 million of one-time cash and non-cash product licensing... More